Celadon Pharmaceuticals

Board of Directors

Alexander Anton, Non-Executive Chairman

Alexander is an experienced AIM director and entrepreneur. Alexander is the former chairman and latterly a non-executive director of Victoria PLC, retiring from that role in 2019. He was Chairman of Summerway Capital Plc from October 2018 to January 2021. Alexander was chairman of The Queen’s Club from 2005-2007 and led the members’ buy out from the Lawn Tennis Association for £35 million in 2007. He is also the founder of Fraser Real Estate and Legacy Portfolio, businesses focused on complex leasehold portfolios.

James (“Jim”) Short, Chief Executive Officer

James is the founder and CEO of Celadon. James has had a successful track record in the construction industry and then in the renewable energy sector. He co-founded the waste to energy business Bio-Gen Power Ltd and sold stakes to Ener-G Holdings PLC in 2007 and to FTSE 100 company International Power in 2008. He sold the company in 2010. Subsequently, James commissioned the feasibility study and obtained planning permission for the development of the £984 million 1,500 megawatt combined cycle gas turbine power plant at Thorpe Marsh in North Doncaster in partnership with Acorn Power and GE. In 2014, he sold the development to GE. Latterly James has been involved in a cyber business that sells its product into a number of NHS hospitals.

Kathleen (“Katie”) Long, Chief Financial Officer

Katie qualified as a Chartered Accountant in 2002 with the Institute of Chartered Accountants Australia and has a degree in Commerce from the University of Melbourne.

Katie started her career as an auditor at Ernst & Young, working on external audits within the financial services sector, and then moved into banking, focusing on the financial reporting of complex structured products under IFRS and US GAAP. In 2008, Katie joined Marwyn Capital LLP as an Investment Manager, where she led and managed a number of the fund’s investments, alongside the provision of corporate finance advice to listed portfolio companies. Katie co-founded Tessera Investment Management Limited in 2012, a specialist provider of in-house transaction management support to organisations undertaking M&A and capital raising activities, where she remains a director and a shareholder.

Katie was previously the Chief Financial Officer of AIM-listed Oxford BioDynamics Plc and is currently also a Non-Executive Director of a venture capital backed cyber security company, RazorSecure Limited.

Robert Barr

Robert (“Robbie”) Barr, Senior Independent Non-Executive Director

Robbie is an experienced operator and director having spent the majority of his executive career with Vodafone PLC where he held senior executive positions, including group financial controller. Robbie is a Senior Advisor to OMERS Private Equity and Infrastructure in Europe and a Non-Executive Director of Associated British Ports Holdings, Chairman of Vue International, the cinema group, and a member of the supervisory committee of rail wagon leasing company VTG AG.

Robbie was formerly executive chairman of Four Seasons Health Care from 2014 to 2018 and of Odeon & UCI Cinemas from 2012 to 2016. From 2009 to 2015 he was a managing director of the private equity firm Terra Firma Capital Partners.

David Firth

David Firth, Independent Non-Executive Director

David is a non-executive director of Parity Group Plc, an IT services and consultancy business and is chairman of its remuneration and audit committees. He is also chairman and audit committee chairman of Best of the Best plc, an organiser of weekly competitions to win cars and other luxury prizes, and a non-executive director and chairman of the audit committee of i-Nexus Global Plc, a strategy execution software company.

Previously he was the finance director of Penna Consulting plc from 1999 to 2016. David has held a number of board positions in public companies over the past 30 years across various sectors including HR consultancy and recruitment, IT services, financial markets, motor retailing and advertising.

Elizabeth (“Liz”) Shanahan, Independent Non-Executive Director

Liz is currently a non-executive director of AIM-listed Inspiration Healthcare Group plc and a former non-executive director of UDG Healthcare plc, a company that was listed on the London Stock Exchange and a constituent of the FTSE 250 up until its £2.8 billion takeover, which completed in August 2021.

Liz is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., who had in 2007 acquired the communications business, Santé Communications, which she founded in 1995. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London and a member of the organisation’s Innovations Advisory Board.

Dr Steven (“Steve”) Hajioff, Independent Non-Executive Director

Steve has been a leader and innovator in healthcare and health policy for thirty years. He was the Chairman of the Representative Body of the British Medical Association (BMA) from 2010 to 2013 and has worked as a Medical Director or Chief Medical Officer in several organisations including Bupa Health Dialog, Totally PLC, Pain Management Solutions Ltd and The Knowde Group.

He previously advised NHS England on specialized services, including rare disease, orphan drugs and low-volume high cost procedures and has been an adviser to the National Institute for Health and Care

Excellence (NICE) in a range of capacities since 2012. He is currently a member of their Quality Standards Advisory Committee.

He was, until recently, a Director of Public Health and a member of the Governing Body of a Clinical Commissioning Group in west London. Steve runs his own consultancy business and specialises in healthcare market access and reimbursement, clinical opportunity analysis and health policy.

Steve is currently the Chief Medical Officer at Sana Life sciences and is a scientific adviser to Phytome Life Sciences. He is also a Senior Lecturer at Imperial College London. He was formerly a member of the Medical Ethics Committee of the British Medical Association; one of the most influential bodies in UK clinical ethics.

In June 2015, the British Medical Association awarded Steve their highest honour, the Gold Medal for Distinguished Merit.